References
- Chaguturu R, Ed. Collaborative innovation in drug discovery: strategies for public and private partnerships. Wiley, New York; 2014.
- Ripke S, Neale BM, Corvin A, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–427.
- Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–1352.
- Flannick J, Beer NL, Bick AG, et al. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet. 2013;45(11):1380–1385.
- Collyar D, Chaguturu R. A renaissance in biomedical innovation: global villages raise effective therapies. Future Med Chem. 2015;7(8):971–974.
- Schreiber SL, Kotz JD, Li M, et al. Advancing biological understanding and therapeutics discovery with small-molecule probes. Cell. 2015;161(6):1252–1265.
- Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173(11):1778–1792.
- Academic Drug Discovery Consortium. Available from: http://www.addconsortium.org/
- Cui L, Su X. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009;7(8):999–1013.
- Lee CH, Kuo WC, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine. 2009;27(5):726–732.
- Lushington GH, Chaguturu R. Biomedical research: a house of cards? Future Med Chem. 2016;8(1):1–5.
- Roy A, Patwardhan B, Chaguturu R. Reigniting pharmaceutical innovation through holistic drug targeting. Drug Discovery World. 2016;Summer. 45–55.
- Chorgade M, Liebman M, Lushington G, et al. Translational chemical biology: Gap assessment for advancing drug discovery, development and precision medicine. Drug Discovery World. 2016/2017;Winter 72–90.